KRAS and neoplasm: Recently, a retrospective pooled analysis confirmed the favorable predictive effect of c.38 G > A KRAS mutation in first line cetuximab-containing chemotherapy [33]: significantly improved PFS (median, 7.4 versus 6.0 months) and tumor response (40.5% versus 22.0) but not survival (median, 15.4 versus 14.7 months).